Home CFRX
0.1694
  Price1.68%   +0.0028
 
loading
Calls Options of CFRX for (Expired in 13 days)
Strike Price Change % Change Volume
favorite 2.50 0.05 0.00 0.00% 0
favorite 5.00 0.06 0.00 0.00% 0
favorite 7.50 0.10 0.00 0.00% 0
Puts Options of CFRX for (Expired in 13 days)
Strike Price Change % Change Volume
favorite
2.50
2.35 0.10 +4.44% 1
favorite
5.00
2.00 0.00 0.00% 0
favorite
7.50
4.90 0.00 0.00% 0
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Cap:    |  Volume (24h):